Department of Pediatric Cardiology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, P.R. China.
Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):7144-7151. doi: 10.26355/eurrev_201908_18760.
This study aimed to compare the efficacy and safety of ulinastatin combined with creatine phosphate sodium and ribavirin combined with creatine phosphate sodium in the treatment of pediatric viral myocarditis.
155 children with viral myocarditis in the Xuzhou Children's Hospital, were retrospectively analyzed. 80 of them received ulinastatin combined with creatine phosphate sodium, and were regarded as observation group; other 75 patients received ribavirin combined with creatine phosphate sodium and were regarded as the control group. The therapeutic efficacy of the two groups was observed, the improved condition of myocardial enzyme indicator and myocardial troponin I (cTn I) in the two groups were compared before and after the treatment.
The total effective rates of the patients in the observation group and the control group were 93.75% and 76.00%, respectively. The clinical efficacy of the observation group was better than that of the control group (p<0.05). The electrocardiogram improvement condition of the observation group was better than that of the control group (p<0.05); after the treatment, the expression levels of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), Creatine Kinase (CK-MB), and cTn I in the observation group were (313.37±9.42) U/L, (29.38±4.97) U/L, (23.67±2.89) U/L, (0.12±0.02) μg/L, respectively. The expression levels of LDH, AST, CK-MB, and cTn I in the control group were (322.43±12.32) U/L, (33.43±5.14) U/L, (26.22±3.37) U/L, (0.24±0.04) μg/L. The levels of myocardial enzyme and cTn I in the observation group and the control group after the treatment were lower than that before the treatment (p<0.05), while the level of myocardial enzyme and cTn I in the observation group after the treatment was significantly lower than that in the control group (p<0.05).
The results indicated that, compared with ribavirin combined with creatine phosphate sodium, ulinastatin combined with creatine phosphate sodium had better clinical efficacy in the treatment of pediatric viral myocarditis. It could significantly improve the level of myocardial enzyme indicator and cTn I, and had certain clinical and promotional values and application values.
本研究旨在比较乌司他丁联合磷酸肌酸钠与利巴韦林联合磷酸肌酸钠治疗小儿病毒性心肌炎的疗效和安全性。
回顾性分析徐州市儿童医院收治的 155 例病毒性心肌炎患儿的临床资料。其中 80 例采用乌司他丁联合磷酸肌酸钠治疗，设为观察组；另 75 例采用利巴韦林联合磷酸肌酸钠治疗，设为对照组。观察两组患儿的治疗效果，比较两组患儿治疗前后心肌酶指标及心肌肌钙蛋白 I（cTn I）改善情况。
观察组患儿总有效率为 93.75%，对照组为 76.00%，观察组患儿临床疗效优于对照组（p<0.05）。观察组患儿心电图改善情况优于对照组（p<0.05）；治疗后，观察组患儿乳酸脱氢酶（LDH）、天门冬氨酸氨基转移酶（AST）、肌酸激酶同工酶（CK-MB）及 cTn I 表达水平分别为（313.37±9.42）U/L、（29.38±4.97）U/L、（23.67±2.89）U/L、（0.12±0.02）μg/L，对照组分别为（322.43±12.32）U/L、（33.43±5.14）U/L、（26.22±3.37）U/L、（0.24±0.04）μg/L。观察组和对照组患儿治疗后心肌酶及 cTn I 水平均低于治疗前（p<0.05），且观察组患儿治疗后心肌酶及 cTn I 水平均明显低于对照组（p<0.05）。
与利巴韦林联合磷酸肌酸钠相比，乌司他丁联合磷酸肌酸钠治疗小儿病毒性心肌炎的临床疗效更好，可显著改善心肌酶指标及 cTn I 水平，具有一定的临床推广应用价值。
